Why Denali Therapeutics Inc.’s (DNLI) Stock Is Up 5.60%
As of Tuesday, October 20, Denali Therapeutics Inc.’s DNLI share price has surged by 5.60%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Denali Therapeutics Inc.’s (DNLI) Stock Is Down 5.98%
As of Monday, August 24, Denali Therapeutics Inc.’s DNLI share price has dipped by 5.98%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Denali Therapeutics Inc.’s (DNLI) Stock Is Down 6.95%
As of Tuesday, July 14, Denali Therapeutics Inc.’s DNLI share price has dipped by 6.95%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Denali Therapeutics Inc.’s (DNLI) Stock Is Down 14.54%
As of Tuesday, July 14, Denali Therapeutics Inc.’s DNLI share price has dipped by 14.54%, which has investors questioning if this is right time to buy.Omar Beirat
Why Denali Therapeutics Inc.’s (DNLI) Stock Is Down 5.44%
As of Friday, July 10, Denali Therapeutics Inc.’s DNLI share price has dipped by 5.44%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | DNLI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,025.9 | $228.4 | 60% |
|
| Shares Out (Mil) | 187.3 | 53.9 | 75% |
|
| Institutional Ownership | 97.1% | 92.9% | 72% |
|
| Float (Mil) | 155.1 | 41.7 | 69% |
|
| Beta | 1.00 | 0.95 | 60% |
|
| Avg Daily Volume (000s) | 1,928 | 582 | 81% |
|
| Price Change (52-week) |
13.6% | 47.6% | 63% |
|
| Growth | DNLI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (55.9%) | (10.1%) | 6% |
|
| EPS (5yr) | (46.3%) | 15.8% | 4 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (46.0%) | (15.7%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 17 | 17 | 17 | |
| Current EPS | ($0.367) | ($2.229) | ($2.417) | |
| Month Ago EPS | ($0.365) | ($2.222) | ($2.419) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.644) | ($2.372) | ($2.533) | |
| Year/Year Chg | (46.1%) | (24.9%) | (41.2%) | |
| Financials | DNLI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4 | $37 | 5% |
|
| Net Income (TTM) (Mil) | ($512) | ($44) | 3% |
|
| EPS (TTM) | ($2.834) | ($1.500) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($434) | ($33) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $60 | $2 | 72% |
|
| Long-Term Debt (Q1) (Mil) | $28 | $4 | 34% |
|
| Enterprise Value (Q1) (Mil) | $3,094 | $177 | 55% |
|
| Valuation | DNLI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.62 | 2.19 | 73% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | DNLI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (44.0%) | (47.1%) | 13% |
|
| ROE | (54.9%) | (54.1%) | 14% |
|
| Liabilities to Assets | 27.9% | 29.1% | 19% |
|
| F-Score | 2 | 2 | 7% |
|
Denali Therapeutics Inc. did not pass any screens on 10/20/2026.
